Anthera Pharmaceuticals Inc.'s blisibimod, a peptibody that targets B-cell activating factor (BAFF) for lupus, slid past the interim futility analysis in the phase III trial CHABLIS-SC1, sending shares on an upward ride that ended Tuesday with the stock (NASDAQ:ANTH) closing at $3.25.